On May 12, 2025 RemeGen Co., Ltd. (688331.SH/9995.HK) reported that the Clinical Trial Application (CTA) for its novel ADC Drug RC278 has been submitted recently and accepted by National Medical Products Administration (NMPA) Center for Drug Reevaluation (CDE) on May 8th (Press release, RemeGen, MAY 12, 2025, View Source;cid=115&id=2650 [SID1234656125]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RC278, independently designed and developed by RemeGen, emerges as a potentially First-in-Class/Best-in-Class ADC molecule. RC278 can specifically recognize a new tumor target and contains an innovative linker-cytotoxicity system, showing broad-spectrum antitumor activity, manageable safety and pharmacokinetic characteristics in the pre-clinical study.

As an important drug candidate in RemeGen’s ADC pipeline, RC278 boasts unique target and differentiated molecule design, demonstrating RemeGen’s progress in ADC technology. RC278 will bring new treatment option for the advanced solid tumor patients.